Koers Shanrong Biotechnology Corp. Other OTC
Aandelen
SRBT
US81946R1077
Holdingvennootschappen
Omzet 2008 | 692K 648K | Omzet 2009 | 1,32 mln. 1,24 mln. | Marktkapitalisatie | 11,62 mln. 10,88 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2008 | -2 mln. -1,87 mln. | Nettowinst (verlies) 2009 | -5 mln. -4,68 mln. | EV/omzet 2008 | 45,1 x |
Nettoschuld 2008 | 2,53 mln. 2,37 mln. | Nettoschuld 2009 | 2,18 mln. 2,05 mln. | EV/omzet 2009 | 10,4 x |
K/w-verhouding 2008 |
-10,5
x | K/w-verhouding 2009 |
-2,03
x | Werknemers | - |
Dividendrendement 2008 * |
-
| Dividendrendement 2009 |
-
| Vrij verhandelbaar | 38,95% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Frank Igwealor
CEO | Chief Executive Officer | 53 | 31-08-21 |
Qingping Zheng
BRD | Director/Board Member | - | - |
Guenter Volgger
PRN | Corporate Officer/Principal | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Frank Igwealor
CEO | Chief Executive Officer | 53 | 31-08-21 |
Qingping Zheng
BRD | Director/Board Member | - | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+179,37% | 6,38 mld. | |
+1,42% | 1,01 mld. | |
+2,12% | 981 mln. | |
+41,91% | 872 mln. | |
+22,16% | 812 mln. | |
+1,82% | 664 mln. | |
+28,22% | 622 mln. | |
+1,80% | 617 mln. | |
-.--% | 600 mln. |